Company profile
tcypherbio Building a pipeline of novel, TCR-based therapeutics.
T-Cypher Bio Limited is a UK company with status active founded in 2015 based in South East England.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AP01 | Transaction MzUyOTUwOTIzN2FkaXF6a2N4
Published 30 Jun 2026 16:16
Last confirmation statement made up date
Last accounts made up date
AP01 | Transaction MzQ0MjQ0ODI3NGFkaXF6a2N4
Published 08 Nov 2024 09:29
CS01 | Transaction MzQ0MTYyMzEzOWFkaXF6a2N4
Published 31 Oct 2024 02:42
Company registered at Companies House
T-Cypher Bio develops TCR (T-Cell Receptor) discovery software designed to identify TCRs for the treatment of tumours and other diseases.
We are a peptide display company identifying potential peptide drugs for a range of chronic diseases Peptides offer the potential to make drugs with the specificity and efficacy of large biologic molecules combined with the smaller dose size, simpler routes of delivery and lower cost of manufacturing found with small molecules. They are, therefore, uniquely suited to the treatment of chronic diseases which impact large patient populations. Our technology supports all of the improvements that can be made to peptides which make them better drugs whilst simplifying the discovery process and accelerating drug development. Peptides have the specificity of antibodies, manufacturing costs analogous to small molecules and simple, safe degradation products. They offer the best of both. Technologies like the Orbit method allow us to identify novel peptides as drug leads for a wide range of indications where peptides haven't previously been seen.
Tcypherbio generates TCR-based therapeutics that have the potential to transform the treatment of solid tumours, autoimmune, inflammatory, and infectious diseases. Their discovery platform generates target screening libraries to identify functionally defined T-cell clones directly from disease tissues, forming the foundation of their expanding pipeline.
successful fund raising, and recruitment of executive team and staff
x
1 Jun 2024 to 30 Nov 2025
The immune system plays a key role in a broad range of disease -- including cancer, infection and autoimmunity. In recent years, treatment approaches which modulate the immune system have proved effective in a range of major diseases. T-cells are a key component of the immune system, with the capability of exquisitely recognising diseased or healthy tissu...
1 Feb 2020 to 31 Oct 2021
We are Orbit Discovery Ltd, a rapidly growing biotechnology company that works collaboratively with its partners to rapidly identify and characterise advanced peptide therapeutic drugs for a range of chronic diseases using a highly efficient in vitro screening technique. We want to develop synthetic biology technology for screening of potential drug targe...
1 Feb 2019 to 31 Oct 2020
Orbit Discovery Ltd was established in November 2015 as a spin-out from Oxford University. The founding IP relates to a peptide display platform and its use for the identification of novel peptides and for the identification of T-cell epitopes in high throughput screens. We provide services identifying and characterising advanced therapeutics for a range ...
1 Jan 2018 to 31 Dec 2018
Display technologies are of great utility in the identification of proteins and other molecules that bind with high specificity and high affinity to targets of interest. These technologies, such as phage display and mRNA or ribosomal display, have revolutionized the development of small peptide therapeutics and also diagnostic tools in applications in can...
